200 related articles for article (PubMed ID: 27037661)
1. Rebound pustular psoriasis after brodalumab discontinuation.
Khemis A; Cavalié M; Montaudié H; Lacour JP; Passeron T
Br J Dermatol; 2016 Nov; 175(5):1065-1066. PubMed ID: 27037661
[No Abstract] [Full Text] [Related]
2. Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases.
Pinter A; Wilsmann-Theis D; Peitsch WK; Mössner R
J Dermatol; 2019 May; 46(5):426-430. PubMed ID: 30786053
[TBL] [Abstract][Full Text] [Related]
3. Brodalumab: A Review of Safety.
Rusta-Sallehy S; Gooderham M; Papp K
Skin Therapy Lett; 2018 Mar; 23(2):1-3. PubMed ID: 29562088
[TBL] [Abstract][Full Text] [Related]
4. Severe myalgia associated with brodalumab treatment in a patient with psoriasis.
Ichiyama S; Matano Y; Hoashi T; Kanda N; Nagayama H; Saeki H
J Dermatol; 2018 Dec; 45(12):e327-e328. PubMed ID: 29782052
[No Abstract] [Full Text] [Related]
5. Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients.
Masson Regnault M; Konstantinou MP; Khemis A; Poulin Y; Bourcier M; Amelot F; Bulaï Livideanu C; Paul C
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1491-1496. PubMed ID: 28585707
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study.
Yamasaki K; Nakagawa H; Kubo Y; Ootaki K;
Br J Dermatol; 2017 Mar; 176(3):741-751. PubMed ID: 27106510
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis.
Galluzzo M; Talamonti M; D'adamio S; Bianchi L
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):679-691. PubMed ID: 28460549
[TBL] [Abstract][Full Text] [Related]
8. Suicidal thoughts end Amgen's blockbuster aspirations for psoriasis drug.
Schmidt C
Nat Biotechnol; 2015 Sep; 33(9):894-5. PubMed ID: 26348946
[No Abstract] [Full Text] [Related]
9. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis.
Fairhurst DA; Sheehan-Dare R
Clin Exp Dermatol; 2009 Apr; 34(3):421-2. PubMed ID: 19309375
[No Abstract] [Full Text] [Related]
10. What Lies Beneath the Face Value of a BOX WARNING: A Deeper Look at Brodalumab.
Hashim PW; Chen T; Lebwohl MG; Marangell LB; Kircik LH
J Drugs Dermatol; 2018 Aug; 17(8):s29-s34. PubMed ID: 30124737
[TBL] [Abstract][Full Text] [Related]
11. Risankizumab-induced paradoxical pustular psoriasis.
McFeely O; Pender E; Victory L; Almutlaq H; Storan E
Clin Exp Dermatol; 2022 Mar; 47(3):616-617. PubMed ID: 34748673
[TBL] [Abstract][Full Text] [Related]
12. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM;
Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
Papp K; Leonardi C; Menter A; Thompson EH; Milmont CE; Kricorian G; Nirula A; Klekotka P
J Am Acad Dermatol; 2014 Dec; 71(6):1183-1190.e3. PubMed ID: 25313095
[TBL] [Abstract][Full Text] [Related]
14. Two cases of skin infection during psoriasis treatment with brodalumab.
Kobayashi M; Nagata M; Oaku S; Kanda N; Tada Y; Aozasa N
J Dermatol; 2018 Mar; 45(3):e51-e52. PubMed ID: 29083051
[No Abstract] [Full Text] [Related]
15. Adalimumab may be better or no worse than methotrexate in the treatment of psoriasis.
Nijsten T; Spuls PI
Br J Dermatol; 2008 Jul; 159(1):257-8. PubMed ID: 18489593
[No Abstract] [Full Text] [Related]
16. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
[TBL] [Abstract][Full Text] [Related]
17. Rebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporine.
Maskatia ZK; Koo J
J Drugs Dermatol; 2007 Sep; 6(9):941-4. PubMed ID: 17941368
[TBL] [Abstract][Full Text] [Related]
18. Development of bullous pemphigoid during treatment of psoriasis with adalimumab.
Stausbøl-Grøn B; Deleuran M; Sommer Hansen E; Kragballe K
Clin Exp Dermatol; 2009 Oct; 34(7):e285-6. PubMed ID: 19438555
[No Abstract] [Full Text] [Related]
19. Dermatitis during efalizumab treatment in a patient with psoriasis vulgaris.
de Groot M; de Rie MA; Bos JD
Br J Dermatol; 2005 Oct; 153(4):843-4. PubMed ID: 16181475
[No Abstract] [Full Text] [Related]
20. Infliximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva).
Thielen AM; Barde C; Saurat JH
Br J Dermatol; 2006 Oct; 155(4):846-7. PubMed ID: 16965444
[No Abstract] [Full Text] [Related]
[Next] [New Search]
